SynthesisFrontiers in nutrition2026
Association between prognostic nutritional index and prognosis in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis.
Synthesis in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to comprehensively evaluate the predictive value of prognostic nutritional index (PNI) for long-term survival in non-small cell lung cancer (NSCLC) patients treated with programmed death receptor-1 and its ligand (PD-1/PD-L1) inhibitors through systematic review and meta-analysis. Methods: A systematic search was conducted in PubMed, Embase, Web of Science, and the Cochrane Library databases up to January 2026. Observational studies assessing the association between PNI and survival outcomes in NSCLC patients treated with PD-1/PD-L1 inhibitors were included. Two investigators independently performed literature screening, data extraction, and methodological quality assessment (using the Newcastle-Ottawa Scale). Heterogeneity was assessed using the pooled hazard ratio (HR) and its 95% confidence interval (CI) in a random-effects model, and subgroup analyses, sensitivity analyses, and publication bias assessments were performed. Results: A total of 14 studies involving 2,106 patients were included. Meta-analysis results showed that a higher PNI was associated with significantly improved overall survival (OS) (HR = 0.46, 95% CI: 0.34-0.64, Conclusion: Current evidence suggests an association between higher baseline PNI and improved survival outcomes in NSCLC patients receiving PD-1/PD-L1 inhibitor therapy. The PNI may serve as a candidate biomarker for risk stratification, but its clinical utility requires validation in prospective studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.